BioCentury | Mar 25, 2013
Company News

NeuroSearch neurology news

...a cardiovascular outcomes trial of the compound, as well as two one-year Phase III trials. ABT-894...
BioCentury | Oct 1, 2012
Company News

NeuroSearch, Teva deal

...a cardiovascular outcomes trial of the compound, as well as two one-year Phase III trials. ABT-894...
BioCentury | Feb 16, 2009
Clinical News

ABT-894: Phase II data

...The partners discontinued the development of ABT-894 for diabetic neuropathic pain after 2 parallel, double-blind, international...
...The M06-850 trial enrolled 275 patients, who received placebo, 1, 2 or 4 mg twice-daily ABT-894...
...60 mg once-daily Cymbalta duloxetine from Eli Lilly and Co. (NYSE:LLY; Indianapolis, Ind.). Last June, ABT-894...
BioCentury | Feb 16, 2009
Clinical News

ABT-894: Phase II data

...The partners discontinued the development of ABT-894 for diabetic neuropathic pain after 2 parallel, double-blind, international...
...M10-014 trial enrolled 129 patients, who received placebo or 6 mg twice-daily ABT-894. Last June, ABT-894...
...June 23, 2008). NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: ABT-894...
BioCentury | Feb 16, 2009
Finance

Ebb & Flow

...off DKK5.50 to DKK170 last week after it and partner Abbott (NYSE:ABT) discontinued development of ABT-894...
BioCentury | Feb 12, 2009
Clinical News

ABT-894 misses diabetic neuropathic pain endpoint

...NeuroSearch (CSE:NEUR) and Abbott (NYSE:ABT) discontinued development of ABT-894 for diabetic neuropathic pain after two parallel...
BioCentury | Jun 23, 2008
Finance

Ebb & Flow

...$32.95 on the week. NeuroSearch (CSE:NEUR) gained DKK12.50 to DKK255 last week after it said ABT-894...
...control Strattera atomoxetine, which is marketed by Eli Lilly (NYSE:LLY). Abbott (NYSE:ABT) has rights to ABT-894...
BioCentury | Jun 23, 2008
Clinical News

ABT-894: Phase II data

...In a double-blind, U.S. Phase II trial in about 200 patients, ABT-894 met the primary endpoint...
...ABT-894 from NeuroSearch. NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: ABT-894...
BioCentury | Jun 21, 2008
Clinical News

ABT-894 meets ADHD endpoint

...NeuroSearch (CSE:NEUR) said ABT-894 met the primary endpoint of a significant improvement vs. placebo in Conner's...
...by Eli Lilly (NYSE:LLY). The double-blind trial enrolled about 200 patients. Abbott has rights to ABT-894...
BioCentury | Sep 17, 2007
Clinical News

ABT-894: Phase II started

...ADHD) in adults. NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Abbott Laboratories (ABT), Abbott Park, Ill. Product: ABT-894...
...improvement, weekly mean of 24-hour worst pain, night pain and morning pain, Global assessments of ABT-894...
Items per page:
1 - 10 of 18